BACKGROUND: Nesiritide (Natrecor, Janssen-Ortho Inc, Canada), or recombinant human B-type natriurtic peptide (BNP), is a molecule identical in structure to endogenous BNP-32. This peptide is secreted from cardiac myocytes in response to volume and pressure overload. While high levels of circulating BNP are measured by commercially available assays during acute decompensated heart failure (ADHF), the detection of alternate, potentially more active, but undermeasured forms of BNP needs to be considered. AIM: The present review summarizes the molecular and physiological effects of nesiritide in the setting of hospitalized patients with ADHF. In particular, an overview of the molecular structure and circulating isoforms of BNP is given, followed by a discussion of the vasodilatory, renal, antagonistic neurohormonal, pulmonary, anti-inflammatory and cardiac remodelling effects of recombinant human BNP. SUMMARY: Nesiritide has beneficial effects in the treatment of ADHF that go beyond the traditional goals of reducing pulmonary capillary wedge pressure, preload and afterload, and relieving symptoms of dyspnea. Therefore, the unique pharmacological profile of this medication provides an additional treatment option for Canadian patients with ADHF.
BACKGROUND: Nesiritide (Natrecor, Janssen-Ortho Inc, Canada), or recombinant humanB-type natriurtic peptide (BNP), is a molecule identical in structure to endogenous BNP-32. This peptide is secreted from cardiac myocytes in response to volume and pressure overload. While high levels of circulating BNP are measured by commercially available assays during acute decompensated heart failure (ADHF), the detection of alternate, potentially more active, but undermeasured forms of BNP needs to be considered. AIM: The present review summarizes the molecular and physiological effects of nesiritide in the setting of hospitalized patients with ADHF. In particular, an overview of the molecular structure and circulating isoforms of BNP is given, followed by a discussion of the vasodilatory, renal, antagonistic neurohormonal, pulmonary, anti-inflammatory and cardiac remodelling effects of recombinant humanBNP. SUMMARY: Nesiritide has beneficial effects in the treatment of ADHF that go beyond the traditional goals of reducing pulmonary capillary wedge pressure, preload and afterload, and relieving symptoms of dyspnea. Therefore, the unique pharmacological profile of this medication provides an additional treatment option for Canadian patients with ADHF.
Authors: W T Abraham; B D Lowes; D A Ferguson; J Odom; J K Kim; A D Robertson; M R Bristow; R W Schrier Journal: J Card Fail Date: 1998-03 Impact factor: 5.712
Authors: W S Colucci; U Elkayam; D P Horton; W T Abraham; R C Bourge; A D Johnson; L E Wagoner; M M Givertz; C S Liang; M Neibaur; W H Haught; T H LeJemtel Journal: N Engl J Med Date: 2000-07-27 Impact factor: 91.245
Authors: L S Marcus; D Hart; M Packer; M Yushak; N Medina; R S Danziger; D F Heitjan; S D Katz Journal: Circulation Date: 1996-12-15 Impact factor: 29.690
Authors: Matthias Schmitt; Prasad Gunaruwan; Nicola Payne; Justin Taylor; Leong Lee; Andrew J M Broadley; Angus K Nightingale; John R Cockcroft; Allan D Struthers; John V Tyberg; Michael P Frenneaux Journal: Arterioscler Thromb Vasc Biol Date: 2004-03-04 Impact factor: 8.311
Authors: Ann M Kapoun; Faquan Liang; Gilbert O'Young; Deborah L Damm; Diana Quon; R Tyler White; Kimberly Munson; Andrew Lam; George F Schreiner; Andrew A Protter Journal: Circ Res Date: 2004-01-15 Impact factor: 17.367
Authors: Andrew Worster; Cynthia M Balion; Stephen A Hill; Pasqualina Santaguida; Afisi Ismaila; Robert McKelvie; Sonja M Reichert; Matthew J McQueen; Lynda Booker; Parminder S Raina Journal: Clin Biochem Date: 2007-08-24 Impact factor: 3.281